Head-to-head evidence
Alirocumab vs Recaticimab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: PCSK9 · full Atherosclerotic Cardiovascular Disease pipeline
Alirocumab · Praluent
Marketed by Regeneron Pharmaceuticals
NCT01507831 · Phase 3 · completed
The study was large (2,341 participants), randomized, quadruple-blind, and placebo-controlled. Its primary clinical safety endpoint was reported, but the registry does not provide a statistical significance test for the comparison, so whether the primary endpoint was met cannot be determined.
Next expected readout: December 2026 · NCT07477704 (registry estimate)
Recaticimab
Developed by Jiangsu Hengrui Pharmaceuticals
NCT04849000 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial with 709 participants, using percentage change in LDL cholesterol as the primary measure. The sponsor reports statistically significant LDL reductions of 45 to 53 percentage points versus placebo across all three dosing regimens.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Alirocumab's landscape · Recaticimab's landscape